ReviewMolecular cancer therapeutics2012
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.
Review in Molecular cancer therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.Frontiers in pharmacology · 2023Review
- Identification of a Metastasis-Associated Gene Signature of Clear Cell Renal Cell Carcinoma.Frontiers in genetics · 2020Article
- Identification of key genes involved in the metastasis of clear cell renal cell carcinoma.Oncology letters · 2019Article
- Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.Current oncology (Toronto, Ont.) · 2018Review
- Cystic Duct Metastasis from Renal Cell Carcinoma.Internal medicine (Tokyo, Japan) · 2018Article
- Emerging Role of MicroRNAs in mTOR Signaling.Cellular and molecular life sciences : CMLS · 2017Review
- Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.Molecular medicine reports · 2015Article
- Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.BMC urology · 2015Article
- RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.Molecular cancer research : MCR · 2015Article
- Adjuvant therapy for renal cell carcinoma: past, present, and future.The oncologist · 2014Review
- Article
- Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Urologic oncology · 2014Article
- Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Cellular and molecular life sciences : CMLS · 2013Review
- Potential biofluid markers and treatment targets for renal cell carcinoma.Nature reviews. Urology · 2013Review
- Tivozanib in the treatment of renal cell carcinoma.Biologics : targets & therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.